Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 7,069 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer, Breast Neoplasms Clear all

Conditions: Breast Cancer
Interventions: CR011-vcMMAE; Drug
Lead sponsor: CuraGen Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Fort Myers, Florida • Lake Worth, Florida • Atlanta, Georgia + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Observational; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Breast Cancer
Interventions: MK-0752, Docetaxel, Pegfilgrastim; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas

Conditions: HER2-normal
Interventions: eribulin mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Lebanon, New Hampshire • New York, New York

Conditions: Breast Reconstruction, Perfusion; Complications, High Risk for Breast Cancer, Genetic Predisposition
Interventions: Minoxidil, Hair mousse; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel; Drug
Lead sponsor: Aventis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 32
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more

Conditions: Metastatic Breast Cancer
Interventions: Docetaxel, Erythromycin Breath Test (ERMBT); Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer
Interventions: Omega-3 Fatty Acids, Placebo Capsule, Diet and Exercise; Dietary Supplement · Other
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Breast Cancer
Interventions: Vagifem; Behavioral
Lead sponsor: Susan Tannenbaum; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hormone Receptor Positive Breast Carcinoma, Postmenopausal, Breast Cancer
Interventions: Tai Chi, Health Education; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Acupuncture Therapy; Procedure
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Chicago, Illinois • Joliet, Illinois • Olympia Fields, Illinois + 1 more

Conditions: Genetic Predisposition to Cancer
Interventions: Patient nudge via text message, Patient nudge via phone call; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Breast Cancer
Interventions: Dasatinib, Letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 27
States / cities: Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more

Conditions: Breast Cancer Female
Interventions: Balloon Brachytherapy, 3D Conformal External Beam Irradiation; Device · Radiation
Lead sponsor: Sentara Norfolk General Hospital; Other
Eligibility: 50 Years and older · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Harrisonburg, Virginia

Conditions: Breast Cancer
Interventions: Acupuncture, Sham acupuncture therapy; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Bevacizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
Interventions: Eribulin, Cyclophosphamide; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Breast Cancer
Interventions: Paclitaxel Albumin Nanoparticle for Injectable Suspension; Drug
Lead sponsor: Veeda Oncology; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: CA 15-3 Assay; Device
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Boca Raton, Florida • Fort Lauderdale, Florida • Wilmington, North Carolina

Conditions: Breast Cancers, Gynecologic Cancer
Interventions: Mindfulness based meditation program; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 101 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Interventions: AGX101; Drug
Lead sponsor: Angiex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Sarasota, Florida • St Louis, Missouri + 4 more

Search by objective public record fields.

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer Risk Assessment and Management Program

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Accelerated Partial Breast Irradiation Study

Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer

Hypertension in Breast Cancer Patients Receiving Bevacizumab

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

A Prospective Longitudinal Breast Cancer Study

The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors